# A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants

> **NCT07214766** · PHASE1 · RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 312 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT07214766
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-17
- **Primary completion:** 2026-07-05
- **Final completion:** 2026-07-05
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07214766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07214766, "A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07214766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*